Kulkarni Samarth sold $202K of CRSP
Kulkarni Samarth (Chief Executive Officer) sold 4,098 shares of CRISPR Therapeutics AG (CRSP) at $49.26 ($0.20M total) on 2026-10-14.
How this was made
The 30-second read
Why it matters
The disclosure provides incremental sentiment information via insider selling, but it does not include any operational update, guidance change, or regulatory/clinical catalyst.
Market read
Traders may briefly reassess sentiment around CRISPR based on the insider sale, but the impact is likely limited given the modest transaction size and lack of additional news.
What to watch
No 10b5-1 plan is stated, so traders may over-interpret intent; also, the article does not disclose total compensation, tax context, or whether other insiders sold/bought around the same time.
Background
This is an SEC Form 4 insider transaction by CRISPR Therapeutics CEO Kulkarni Samarth.
Ticker impact
CRISPR Therapeutics CEO Kulkarni Samarth sold 4,098 shares in an open-market transaction worth $201,867.48 on 2026-10-14.
Likely limited downside pressure as traders weigh the insider sale against broader fundamentals.
The filing is a primary SEC Form 4 disclosure, but the dollar amount is relatively small and the article provides no accompanying operational or guidance catalyst.
Market effects
Minimal, as this is company-specific insider activity without sector-wide signal.
None indicated.
None indicated.
Counterpoint
The sale could be for diversification or liquidity needs and may not reflect negative expectations, especially without any other negative company news in the filing.
Key entities
- issuerCRISPR Therapeutics AG
Company whose CEO filed the Form 4 insider sale.
- insiderKulkarni Samarth
CEO and director who sold shares.
